Skip To Main Content
Annalen Bleckmann on Muck Rack

Annalen Bleckmann

As seen in: Nature, MDPI, Genome Medicine, BioRxiv
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Annalen

Contact Annalen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

|
By Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Stefanie Groepper, Mathias Haenel, Judith Hecker, Max-Felix Häring, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Manuel Ruh, Heiko Schuster, Olga Veremchuk, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Cedrik Michael Britten, Carsten Reinhardt
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04455-x, published online 31 May 2026. In the version of the article initially published, in the “Phase 1a dose escalation” column in Fig. 2, the fifth dose was listed as “0.054 mg” but should have been “0.54 mg”. This correction has been made to the HTML and PDF versions of the article.
Open in Who Shared Issue with article?

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

|
By Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Judith Hecker, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Manuel Ruh, Heiko Schuster, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Carsten Reinhardt, Stefanie Groepper, Mathias Haenel, Max-Felix Häring, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Olga Veremchuk, Cedrik Michael Britten
| Nature Verified
Abstract IMA401 is a T cell receptor (TCR)-based next-generation bispecific T cell engaging receptor (TCER) targeting an HLA-A*02:01-presented peptide derived from MAGE-A4/MAGE-A8 with its high-affinity TCR-based domain, incorporating a low-affinity T-cell-recruiting domain and an optimized Fc domain to prolong half-life.
Open in Who Shared Issue with article?

Deciphering BRCAness Phenotype in Cancer: A Graph Convolutional Neural Network Approach with Layer-wise Relevance Propagation Analysis

|
By Jingyu Yang, Hryhorii Chereda, Jurgen Donitz, Annalen Bleckmann
| BioRxiv
Abstract The concept of BRCAness describes tumors that, although lacking BRCA mutations, exhibit similar molecular vulnerabilities, particularly in the context of homologous recombination repair deficiencies. Patients which display BRCAness are often sensitive to treatments like PARP inhibitors. Here we aim to define BRCAness based on gene expression data of the tumors.
Open in Who Shared Issue with article?
See all 6 articles